Usually, acute organ rejection
is mediated by T-cells by either through T-cell-derived lymphokines or T-cell-mediated cell lysis .
The DART study (Circulating Donor-Derived Cell-Free DNA in blood for diagnosing Acute Rejection in Kidney Transplant Recipients) (NCT02424227) is a prospective, observational clinical study designed to collect prospective data on levels of dd-cfDNA in subjects with stable function of the transplanted organ, experiencing acute organ rejection
and non-rejection organ injury as well as following changes in immunosuppressive treatment.
In the study, Zortress prevented acute organ rejection
and preserved kidney function while allowing, on average, 60% lower doses of the CNI cyclosporine to be used compared with the control regimen of mycophenolic acid (MPA) with full dose cyclosporine and corticosteroids.
Today, Novartis says it has the broadest portfolio of immunosuppressants on the market, including such products as Myfortic (mycophenolic acid) delayed-release tablets, indicated for kidney transplants, and Simulect (basiliximab), designed for the prevention of acute organ rejection
. That portfolio is further expanded with the addition of tacrolimus capsules, the company points out.
Researchers from the PROOF Centre for Excellence and Vancouver Coastal Health Research Institute, funded by Genome B.C., have discovered that blood from heart and kidney transplant patients has genetic biomarkers that can diagnose and predict acute organ rejection
. Biomarkers in Transplantation, a research initiative that will allow doctors to identify patients rejecting transplanted organs with a simple blood test, is making use of advanced genomic, proteomic, and computational tools to develop the test, which will diagnose rejection before acute organ rejection
occurs, allowing doctors to intervene early and to personalize a patient's immunosuppressant therapy.
CellCept was first approved for use in combination therapy for the prevention of acute organ rejection
in kidney transplantation in 1995 and has since been approved worldwide for prevention of organ rejection in adult kidney, heart and liver transplantation.
MADRID -- OTC supplements can stimulate the immune system and trigger acute organ rejection
in transplant recipients, as seen in a series of five cases at one hospital.
Reduced cyclosporine concentrations have been documented when orlistat and cyclosporine are taken together, and the FDA has received postmarketing reports of reduced cyclosporine concentrations and two cases of acute organ rejection
in orlistat users.
Although acute organ rejection
is seen with decreasing frequency after the first year following lung or heart-lung transplantation, it can occur at any time for the rest of the transplant patient's life.
Rapamune is indicated for the prevention of acute organ rejection
in kidney transplant patients and is recommended to be used in a regimen that includes cyclosporine and corticosteroids.
But the surgical department at Loyola University Medical Center in Maywood, Ill., where the study was performed, has halted preoperative administration of OKT3, reserving it instead as a last resort for patients who show signs of acute organ rejection
Rapamune was approved by the FDA in September 1999 for use in combination with cyclosporine and corticosteroids for the prevention of acute organ rejection
in kidney transplant patients.